Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Biotech
Roivant's inflammatory med is back on track with ph. 2 NIU data
Roivant CEO Matt Gline said the company is constantly considering new indications to add to brepocitinib's development plan.
Max Bayer
Apr 2, 2024 10:37am
Idorsia bags $350M upfront from Viatris for 2 late-phase assets
Feb 28, 2024 7:56am
Galapagos halts lupus CAR-T work, confirms 100 layoffs this year
Feb 23, 2024 8:28am
Kyverna CEO: 'We're in the next phase of medicine'
Feb 9, 2024 1:57pm
Precision deals out CAR-T autoimmune rights to TG for $10M
Jan 9, 2024 10:14am
AbbVie agrees to end Alpine study early in return for fee cuts
Dec 22, 2023 5:40am